4SINGHAL S, MEHTA J, DESIKAN R, et al. Antitumor activity of thalidomide in retractory multiple myeloma[J]. N Engl J Med, 1999, 341:1565-1571.
5PARMAN T, WILEY MJ, WELLS PG, et al. Free radial-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity[J]. Nature Medicine, 1999,5 (5) : 582-585.
6GEITZ H, HANDT S,ZWINGENGER K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade[J]. Immunopharmacology, 1996,32,213-221.
7DAVIES FE, RAJE N, HIDESHIMA T, et al. Thalidomide and immunomodu-latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J]. Blood,2001,98(1) :210-216.
8HIDESHIMA T, CHAUHAN D, SHIMA Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to convention-al therapy[J]. Blood,2000,96 : 2943-2950.
9Bladé J,Fernández-Llama P,Bosch F,et al.Renal failure in multiple myeloma:presenting features and predictors of outcome in 94 patients from a single institution[J].Arch Intern Med,1998,158(17):1889-1893.
10Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21):1565-1571.
